Objectives: The objective of this study is to assess the acceptance of morbidity endpoints by the Institute for Quality and Efficiency in Healthcare (IQWiG) within the early benefit assessment in Germany. The analysis focuses on morbidity endpoints (ME) for oncology substances compared to non-oncology substances: (1) how many ME have been accepted? (2) In how many cases has IQWiG determined an additional benefit based on ME? MethOds: All benefit assessments published by the Federal Joint Committee (G-BA) between 01/01/2011 and 12/05/2015 have been considered (n= 126). Of those, 80 were excluded from the analysis due to one of the following reasons: orphan drug designation, no dossier submitted or incomplete evaluation by the IQWiG (due to missing data). Data analyzed: number of accepted ME as proportion of all submitted endpoints; additional benefit based on accepted ME; percent of assessments in which at least one ME was accepted. Results: In total, 19 oncology and 27 non-oncology assessments have been included into the analysis. For the 19 oncology assessments, a total of 76 ME had been submitted. IQWiG accepted hereof 20 ME (≈26%). Accepted ME include: pain, skeletal-related complications and symptoms. The IQWiG determined an additional benefit for six assessments based on ME (6/19≈32%). For the 27 non-oncology assessments, 127 ME had been submitted. IQWiG accepted 79 (≈62%) including: strokes, cardiovascular events and relapse-related events. For non-oncology substances, IQWiG determined an additional benefit for thirteen assessments based on ME (13/27≈48%). At least one endpoint was accepted in 83% of oncology assessments and in 100% of benefit assessments in all other indications. cOnclusiOns: Though the rate of accepting ME in oncology indications is numerically lower (32% vs. 48%), the difference does not reach statistical significance (p= 0.36 Fisher's exact test).
PRM7 cOMPARisOn Of TReATMenT-RelATed AdveRse evenTs RecORded in AdMinisTRATive clAiMs dATA WiTh ThOse RecORded in elecTROnic MedicAl RecORds fOR MulTiPle MyelOMA PATienTs
Irwin DE 1 , Varker H 2 , Farr AM 2 1 Truven Health Analytics, Chapel Hill, NC, USA, 2 Truven Health Analytics, Bethesda, MD, USA Objectives: Multiple myeloma patients often experience adverse events (AEs) related to treatment with novel therapies or traditional chemotherapy. Observational studies frequently use administrative claims data or electronic medical records (EMR) to assess potential AEs. The purpose of this analysis is to compare the occurrence of AEs identified in claims data with those recorded in an oncology EMR. MethOds: Multiple myeloma cases (n= 278) in the MarketScan Oncology EMR-Claims Linked Dataset who received novel or traditional chemotherapy were included. The index date was the first date of medication administration/order and patients were followed for AEs, including neutropenia, thrombocytopenia, venous thromboembolism (VTE) and diarrhea, until a > = 90 gap in all medications for the first regimen. Results: Neutropenia and thrombocytopenia were recorded less often in claims (neutropenia 9%; thrombocytopenia 7%) compared to EMR data (neutropenia 12%; thrombocytopenia 11%). Neutropenia and thrombocytopenia are monitored by oncologists with lab values and this may lead to more frequent recording of less severe AEs in the EMR not reflected in claims data. VTE and diarrhea were recorded more often in the claims (VTE 9%; diarrhea 7%) compared to the EMR (VTE 4%; diarrhea 4%). A VTE diagnosis may likely result in hospitalization and patients with diarrhea may seek care outside of their oncology practice; hence, claims data may capture additional diagnoses assigned by clinicians other than oncologists. Overall, the highest proportions of AEs were found with the linked data containing both the claims and EMR (neutropenia 19%, thrombocytopenia 16%, VTE 10%, diarrhea 11%). cOnclusiOns: AEs typically monitored by lab values ordered by oncologists were recorded more often in EMR data and AEs potentially diagnosed by clinicians in settings outside the oncology practice were recorded more often in the claims data. The linked claims-EMR data provided the most complete assessment of potential treatment-related AEs.
PRM8 nOn-cOMPARATive TRiAls TO suPPleMenT neTWORk MeTA-AnAlyses using ARM-sPecific MeTA-RegRessiOn: An APPlicATiOn TO cOMbinATiOn TheRAPies in hiv
Kanters S 1 , Druyts E 2 , Jansen JP 3 , Mills EJ 4 , Thorlund K 1 1 Redwood Outcomes, Vancouver, BC, Canada, 2 University of British Columbia, Vancouver, BC, Canada, 3 Redwood Outcomes, San Francisco, CA, USA, 4 Stanford University, Stanford, CA, USA Objectives: There is a growing call for the use of endonodal trials within network meta-analyses (NMA), such as for informative priors or improved connectivity. Endonodal trials can also be used to further inform arm-specific meta-regression coefficients, which may be used to simplify node definitions in combination therapy. We applied this concept to a network of first line antiretroviral therapy (ART) to determine if efavirenz (EFV) still belongs in the preferred regimen. MethOds: We conducted a systematic search of electronic databases up to March 1, 2015. Nodes were defined as specific antivirals rather than ART regimens, which simplified interpretation of modeling and results. Backbone regimens were categorized and arm-specific meta-regression used to adjust estimates accordingly. The alternative approach was to simply reduce the evidence base to trials that did not differ with respect to backbones. The most notable trial to differ in backbones was the SINGLE trial comparing EFV to dolutegravir (DTG), central to the research question. Results: A total of 71 trials with 35,270 randomized patients informed the evidence base. DTG was found to be superior with respect to viral suppression at all time points ( GE Healthcare, Marlborough, MA, USA, 4 CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA Objectives: The decision to utilize a particular product may depend on formal hospital guidelines, physician practice patterns, negotiated reimbursement schedules with insurance companies, and other local (geographic and/or hospital) characteristics. These elements are mostly unobservable for the purpose of statistical inference. A hospital fixed-effects model specification, in essence, controls for unobservable within-hospital time-invariant characteristics. Focusing on the relationship between iso-osmolar contrast media (CM) and low-osmolar CM agents (LOCM) and renal failure events in patients undergoing inpatient interventional procedures, this study highlights the importance of controlling for such factors by comparing statistical specifications with and without hospital fixedeffects. MethOds: The Premier database was used to identify patients between January 2008 and September 2013. Eligible patients had a primary procedure of angioplasty defined by International Classification of Diseases, 9th Revision (ICD-9) and/or Current Procedural Terminology (CPT®) codes, inpatient admission, and LOCM or iso-osmolar CM agent. Renal failure during the visit was determined by ICD-9 diagnosis codes. Two different statistical approaches were employed to assess the relationship between renal failure and CM use -Ordinary Least Squares (OLS) cross-sectional and hospital fixed-effects model specification. Results: A total of 385,290 interventional procedure visits met the inclusion criteria. The unadjusted univariate analysis showed 1.7% (p< 0.01) more renal events in the iso-osmolar CM cohort compared to LOCM. The most saturated (OLS) cross-sectional analysis showed 1.4% (p< 0.01) fewer renal events in the iso-osmolar CM cohort compared to patients who received LOCM. Controlling for unobserved heterogeneity across hospitals using the most saturated hospital fixed-effect specification, we found 2.3% (p < 0.01) fewer renal failure events with iso-osmolar CM. cOnclusiOns: This study illustrated the importance of controlling for observable and for unobservable, within-hospital time invariant characteristics through a hospital fixed-effects specification when the decision-making factors for selection of CM may vary from hospital to hospital. Objectives: Alzheimer's disease (AD), the most common form of dementia, is a degenerative disorder of the brain that leads to memory loss. Oxidative stress is a hallmark of AD. This study aims to identify the genetic alterations of AD by using the conventional cytogenetic technique by Trypsin G-banding and molecular analysis of presenilin 1 (PS1) genotype by PCR. The role of selected ions related to energy metabolism as a consequence of oxidative stress in the deterioration accompanied in AD patients were also analyzed. MethOds: The present study includes 49 AD patients and the subjects were categorized in two groups (14 Early-Onset AD) patients and (31 Late-Onset AD) patients, in order to investigate the possible cytogenetic and molecular damage. The gels were developed by staining with silver nitrate. Results: The Late-Onset AD patient shows higher total CA level when compared to Early-Onset AD patient. A comparison of the frequencies for PS1 genotypes among the Early-Onset AD and Late-Onset AD subjects demonstrated a significant difference between the two groups. cOnclusiOns: The strong association of PS1 with Late-Onset AD patients called attention to the importance of genetic studies in AD and the possible roles of PS1 in the progression of this disease. Based on the contributing effects of PS1 in AD pathogenesis, targeting PS1 may provide new opportunities for AD therapeutic strategies. Key Words: Early-Onset Alzheimer's disease patient, Late-Onset Alzheimer's disease patients, PS1, PCR -RFLP
PRM4 A sTudy On cyTOgeneTic And MOleculAR AnAlysis Of PResenilin 1 (Ps1) gene in AlzheiMeR's diseAse

PRM5 hOW gOOd ARe PhysiciAns And chART RevieWs AT cAPTuRing heAlTh ResOuRces And dRug uTilisATiOn by PATienTs? ResulTs Of The PgRx-3 PROsPecTive ReAl WORld dATAseT vAlidATiOn sTudy
Grimaldi-Bensouda L 1 , Rossignol M 2 , Worsfold A 3 , Nordon C 1 , Abenhaim L 3 1 LASER Research, Paris, France, 2 McGill University, Montreal, QC, Canada, 3 LASER Analytica,
London, UK
Objectives: To compare physicians and patient's reports of health resource utilisation using the PGRx-3 datasets. MethOds: PGRx (Pharmacoepidemiologic General Research eXtension) is a multiusers, multi-countries, prospective Real World Datasets originally assembled for effectiveness and relative risk of medicines research. In 2015, PGRx was extended to HEOR research in six countries (France, UK, Italy, Germany, Spain and in the US). Diseases studied with the PGRx methodology are: acute coronary syndrome, arrhythmias, stroke, lupus, rheumatoid arthritis, multiple sclerosis, Guillain Barré Syndrome, type I diabetes, autoimmune thyroiditis, depression and suicide attempts, paediatric autoimmune disorders, breast cancer, prostate cancer (on-going) and others. Patients are recruited by boardcertified specialists or general practitioners and they can fill self-questionnaires. More than 65% consenting patients also undergo a telephone interview. All PGRx datasets are submitted for ethics and privacy protection committees' approval in the contemplated countries. Medical records of more than 5,000 patients have been obtained in a series of validation studies including several of the PGRx disorders and results compared to interviews of the same patients on health resources and drug utilisation. Results: An agreement superior to 95% between patients and their physician's medical records was observed for report of chronic drug use and vaccines, but the agreement was low (< 30%) for drugs available OTC or in the patients' pharmacy (eg: NSAIDs) and for patients' health resources utilisation (eg: physician visits) (agreement less than 25%). cOnclusiOns: Physicians have poor knowledge of acute drug use and of health resource utilisation by patients. Patient interviews are more valid sources of information for health economics and outcomes research than chart reviews codes as independent variables and the logit of progression degree as a dependent variable. Results: 1,436 target patients were extracted from the database. When the actual progression degree is over 80%, the estimated progression degree rises with the actual degree, however, at the lower progression degrees, the estimated degree was excessively overestimated. cOnclusiOns: We have developed a model to estimate the progression degree in colon cancer. The model estimates the progression degree well only for the last phase patients. The model should further be improved to minimize the bias at the lower degree.
PRM12 beyOnd The Middle: evAluATing suRROgAcy Of clinicAl TRiAl endPOinTs AcROss TRiAl duRATiOns
Wasserman M 1 , Amin A 2 1 Double Helix Consulting, New York, NY, USA, 2 Double Helix Consulting, London, UK Objectives: Overall survival (OS) remains the gold standard measure of clinical efficacy for oncology clinical trials due to its objective nature and consistency between diseases and treatments. However, given recent advances in treatments, and prolonged survival, OS benefits are becoming more challenging to establish, requiring more extensive follow-up. A number of methods to test this rationale have been developed but these often lack adequate data, relying solely on mean or median survival. Recognising these limitations, we developed an alternative methodology whereby surrogacy is established over time, to ensure that a surrogate is not only valid at the mean, but also throughout treatment duration. MethOds: A number of different survival points were derived from selected oncology trials by digitizing available survival curves. PlotDigitizer 2.6.4 software was used to establish time points for 10%, 25%, 50%, 75%, and 90% OS and progression-free survival (PFS). Correlation and regression analysis were evaluated at these percentiles based on survival times. Patient populations between the clinical trials were comparable to one another. Statistical analysis was conducted in STATA 12. Results: Correlation analysis found the strongest association between PFS and OS between 75% and 25% survival (0.865 to 0.953; p< 0.01), with a weak association at 90% survival (0.61; p= 0.096). Regression analysis also found that PFS had the largest influence on OS between 75% and 25% survival (R2> 0.75). cOnclusiOns: Given the varying nature of how patients progress across and within types of therapies, it is essential to ensure the surrogacy of the endpoint across the full trial duration. For example, patients may progress early on in a disease and surrogacy may not be consistent across different time points. Additionally, in evaluating older studies, using this approach of scanning survival data will provide a richer picture of the disease area that may no longer be available from authors or research institutions.
PRM13 neTWORk MeTA-AnAlysis Of MulTiPle OuTcOMes incORPORATing dOse-RelATed cOnsTRAinTs: APPlicATiOn TO OveRAcTive blAddeR syndROMe
Owen RK, Tincello DG, Bujkiewicz S, Abrams K University of Leicester, Leicester, UK bAcKgROund: Overactive bladder(OAB) is characterized by symptoms of urgency, incontinence, frequency and nocturia. With the syndromic nature of the condition, clinical trials often solely report the most effective outcome i.e. the symptom with the largest improvement. As a result different interventions are evaluated for different outcomes, which can have severe implications for network meta-analyses, and consequently, decision-making. Objectives: To evaluate the use of multivariate network meta-analysis(MVNMA) to identify the most effective intervention for treating OAB syndrome. MethOds: Using Bayesian Markov Chain Monte Carlo methods, we developed MVNMA accounting for the correlation between multiple outcomes to predict treatment effects for missing data. We extended this model to incorporate the exchangeability between treatment effects of the same intervention with different methods of administration (e.g. immediate release, extended release, intravesical etc.) and incorporated dose-response constraints on increasing doses. The outcomes of interest were mean change from baseline in incontinence, and urgency episodes. Results: Independently, the datasets included 109 and 56 trials, evaluating 93 and 51 interventions, for incontinence and urgency episodes respectively. Sacral nerve stimulation appeared to be the most effective intervention for reducing incontinence with an estimated mean reduction of -8.9(95%CrI:-10.9,-7) episodes per 24hours relative to placebo. For urgency, sacral nerve stimulation was disconnected from the network and thus could not be not evaluated. Borrowing information between outcomes, the dataset for multivariate analyses included 117 trials evaluating all 95 treatments for OAB. Sacral nerve stimulation appeared to be the most effective intervention for both incontinence and urgency episodes with an estimated mean reduction of -8.3(95%CrI:-10.1,-6.9) and -9.1(95%CrI:-10.5,-7.3) episodes, respectively. cOnclusiOns: Sacral nerve stimulation appeared to be the most effective intervention for treating OAB symptoms. MVNMA allowed us to evaluate all interventions across all outcomes, and in this case also increased precision in treatment effect estimates. Further work includes adjustment for baseline severity.
PRM14 The vAlue Of PROgRessiOn-fRee suRvivAl (Pfs) As An endPOinT in OncOlOgy TRiAls
Quinn C 1 , Palmer S 2 , Bruns J 3 , Grant C 1 , Sykes D 4 , Kaura S 5 1 PRMA Consulting, Fleet Hampshire, UK, 2 University of York, Heslington, York, UK, 3 German Cancer Society, Berlin, Germany, 4 PRMA Consulting, Hampshire, UK, 5 Celgene Corporation, Summit, NJ, USA Objectives: The clinical endpoints selected for oncology trials have to meet the needs of diverse stakeholders: patients, clinicians, regulators, and HTA agencies, each with a different perspective. PFS is becoming a more widely accepted measure of treatment efficacy, but there is tension between regulators and payors regarding its acceptability. This study investigated PFS as a valid and credible endpoint from the perspectives of relevant decision-makers. MethOds: Published and gray literature (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) were searched for regulatory and HTA guidance on PFS as an endpoint.
We identified examples of decisions by regulators and HTA agencies in which PFS tended to be protective of discontinuations due to adverse events relative to standard dose EFV. Use of arm-specific regression supplemented by endonodal trials led to tighter confidence intervals facilitating decision-making. Specifically, DTG was consequently superior to EFV with respect to CD4 cell counts and raltegravir was distinguishable from EFV when it was not otherwise. cOnclusiOns: Making full use of available evidence is the focal strength of NMA methodology. Therefore, we recommend use of endonodal trials to further supplement evidence bases requiring arm-specific meta-regression.
PRM9 cRiTicAl APPRAisAl Of ReAl WORld evidence -A RevieW Of RecOMMended And cOMMOnly used TOOls
Quigley JM 1 , Thompson JC 2 , Halfpenny NJ 2 , Scott DA 1 1 ICON Health Economics and Epidemiology, Oxford, UK, 2 ICON Health Economics, Oxford, UK Objectives: In an absence of randomized controlled trials (RCTs) and to verify RCT evidence, health technology assessment (HTA) agencies commonly rely on realworld (RW) studies to provide efficacy evidence for healthcare interventions. RW study designs can introduce considerable bias into a systematic review (SR) and several methodologies exist to evaluate the risk of bias in such studies. We conducted a series of reviews to identify which tools are commonly used and which are recommended by HTA bodies. MethOds: A targeted search of SRs including RW studies, conducted in MEDLINE and EMBASE (OVID SP), identified reviews published January 2013-June 2015. Studies identified were reviewed to determine which appraisal tool was used. Secondly, recommendations for the critical appraisal of RW studies by expert review groups (Cochrane, CRD) and HTA bodies (NICE, SMC, NCPE, AWMSG, IQWiG, PBAC, AMCP, AHRQ and CADTH) were reviewed. Results: 1885 studies were identified and screened. Commonly used tools included Downs & Black, Chalmers, the Newcastle-Ottawa Scale, and the CriSTal checklist. Neither Cochrane nor CRD recommend a particular risk of bias instrument. The AHRQ developed the MORE checklist following a SR of existing critical appraisal tools. Of the other HTA bodies only CADTH recommend use of a specific critical appraisal tool; SIGN 50 (for cohort or case-control studies). The tools identified examine a variety of criteria including reporting, external validity, bias, confounding, and power. cOnclusiOns: There is no consensus on a preferred instrument that allows for the assessment of all types of RW evidence and critical appraisal of RW evidence is often omitted from HTA submissions. There is thus a need for cross communication between groups to reach a consensus and develop a suitable tool. Until a suitable tool is developed, reviewers should select the most appropriate checklist for the design of the studies identified in a particular SR.
PRM10 dOes ATTRiTiOn in subjecT-bAsed sTudies Of dRug sAfeTy leAd TO biAs RelATed TO MORbidiTy?
Pignot M 1 , Klamert A 2 , Pisa G 1 , Potthoff P 3 1 Kantar Health, Munich, Germany, 2 Kantar Health Germany, Munich, Germany, 3 Kantar Health,
Munichn, Germany
Objectives: Sample quality in prospective long-term drug safety studies can be impaired by selective lost-to-follow-up. Attrition will especially bias the sample, when patients with relevant risk factors selectively drop out. In this case, effects in endpoints cannot be related to study-relevant independent variables. The present contribution will demonstrate how careful follow-up procedures can prevent disease-related drop-out bias of the sample. MethOds: For a long-term prospective safety study of new Oral Contraceptive (OC) 25,213 women aged 20 to 40 years were enrolled from gynecological practices in Germany. The women filled-in a baseline questionnaire and were followed-up over two years with four follow-up questionnaires in total. Whenever safety-relevant signs were reported in the questionnaires, physicians validated the report. After two years 12,823 women were still in the sample and completed the fourth questionnaire. Disease differences between the "Retained" and the "Lost" group, which could indicate sample bias, were analysed using multivariate methods. Results: The "retained" and the "lost-to-follow-up" group did not differ in initial disease status or in risk factor at study start: High blood pressure: 2.9% in "Retained Group"; 2.7% in "Lost Group" (phi= .006; n.s.), diabetes : 0.6% vs. 0.6% (phi= .001; n.s.), high cholesterol: 2.6% vs. 2.4% (phi= .007; n.s.),venous thrombosis : .8% vs. .8% (phi= .002; n.s.), smoker-rate : 34.9% vs. 42.3% (phi= .127), BMI> 30: r= .004 (n.s.), age r= .048 (n.s.). The results show that drop-out of the initial sample is not related to study relevant morbidity and that sample bias cannot be concluded. cOnclusiOns: Careful follow-up methods guarantee low lost-to-follow-up in longterm prospective studies of drug safety. Since drop-out cannot be attributed to study-relevant confounders, attrition does not lead to sample bias.
PRM11 esTiMATiOn Of The PROgRessiOn Of cOlOn cAnceR by jAPAnese lARge-scAle insuRAnce benefiTs dATA AnAlysis
Iwasaki K 1 , Arata H 1 , Soeda J 2 , Yanai T 2 , Hiroi S 3 1 Milliman, Tokyo, Japan, 2 Takeda Pharmaceutical Company Limited, Tokyo, Japan, 3 Takeda Pharmaceutical Company Ltd., Tokyo, Japan Objectives: Accurate determination of the progression degree in colon cancer is of paramount importance for the decision making in treatment policy. However, it had been difficult to extract the exacerbation status from the real-world data. The objective of the study was to develop the model to determinate the progression degree using the insurance benefits data in Japan. MethOds: We conducted analyses using claims data provided by Medical Data Vision Co., Ltd. We extracted target patients by the criteria those who meets all of the following conditions; at least one colon cancer diagnosis (ICD-10 code C18~20), tractable from the first diagnosis to death, and have at least 365 days of observation. We set the progression degree as a scale from 0% to 100%. The degree of 100% indicates the patient death. For the first diagnosis, the scale was adjusted based on the patient's condition. We have developed a linear regression model by using the medication frequency of ATC
